Area of research
Genetics · Cancer Research
Research interest
Mark Robson, MD, is an Associate Attending Physician of the Clinical Genetics and Breast Cancer Medicine Services in the Department of Medicine at Memorial Sloan-Kettering Cancer Center. He received his B.Sc. from Washington and Lee University and his M.D. from the University of Virginia. He performed residency and fellowship training at Walter Reed Army Medical center before coming to Memorial Sloan-Kettering in 1996. He is currently the Clinic Director of the Clinical Genetics Service and the chair of the Cancer Genetics Subcommittee of the American Society of Clinical Oncology.
Functional evaluation and clinical classification of BRCA2 variants
Breast cancer germline multigene panel testing in mainstream oncology based on clinical–public health utility: ESMO Precision Oncology Working Group recommendations
Invasive lobular carcinoma: Strategies and perspectives from the lobular breast cancer research group
Corrigendum to “Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group”
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline
Automated real-world data integration improves cancer outcome prediction
First-in-Human Evaluation of Site-Specifically Labeled<sup>89</sup>Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer
Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing
Invasive lobular breast cancer: Focus on prevention, genetics, diagnosis, and treatment
TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2.
OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
Association of the <scp> <i>CHEK2</i> </scp> c. <scp>1100delC</scp> variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer‐specific survival
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study
Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
Breast Cancer Screening Strategies for Women With <i>ATM, CHEK2</i>, and <i>PALB2</i> Pathogenic Variants
Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients
Disparities in cancer genetics care by race/ethnicity among pan‐cancer patients with pathogenic germline variants
Allelic dosage of <i>RB1</i> drives CDK4/6 inhibitor treatment resistance in metastatic breast cancer.
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative
Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer
Coronary Artery Disease in Young Women After Radiation Therapy for Breast Cancer
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors